Transdermal methimazole treatment in cats with hyperthyroidism
The objectives of this study were to assess serum thyroxine concentrations and clinical response in hyperthyroid cats to treatment with transdermal methimazole, and to determine if further investigation is indicated. Clinical and laboratory data from 13 cats with hyperthyroidism were retrospectively...
Gespeichert in:
| Veröffentlicht in: | Journal of feline medicine and surgery 2003-04, Vol.5 (2), p.77-82 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 82 |
|---|---|
| container_issue | 2 |
| container_start_page | 77 |
| container_title | Journal of feline medicine and surgery |
| container_volume | 5 |
| creator | Hoffmann, G Marks, S.L Taboada, J Hosgood, G.L Wolfsheimer, K.J |
| description | The objectives of this study were to assess serum thyroxine concentrations and clinical response in hyperthyroid cats to treatment with transdermal methimazole, and to determine if further investigation is indicated.
Clinical and laboratory data from 13 cats with hyperthyroidism were retrospectively evaluated. Methimazole (Tapazole, Eli Lilly) was formulated in a pleuronic lecithin organogel (PLO)-based vehicle and was applied to the inner pinna of the ear at a dosage ranging from 2.5
mg/cat q 24
h to 10.0
mg/cat q 12
h. During the treatment period, cats were re-evaluated at a mean of 4.3 weeks (recheck-1), and again at a mean of 5.4 months (recheck-2).
Clinical improvement was observed, and significant decreases in thyroxine concentrations were measured at recheck-1 (mean: 39.57
nmol/L, SEM: 14.4, SD: 41.2) and recheck-2 (mean: 36.71
nmol/L, SEM: 13.9, SD: 45.56) compared to pretreatment concentrations (mean: 97.5
nmol/L, SEM: 11.42, SD: 39.5). No adverse effects were reported. |
| doi_str_mv | 10.1016/S1098-612X(02)00095-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_AFRWT</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10822224</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1016_S1098-612X(02)00095-5</sage_id><els_id>S1098612X02000955</els_id><sourcerecordid>73162729</sourcerecordid><originalsourceid>FETCH-LOGICAL-c507t-9aad0ea0b3f9b6457c851fd398a1e8e625dcfe73aa040022105823445d5c971b3</originalsourceid><addsrcrecordid>eNqFkM1OGzEURi3UigTaR6CaVQWLgWt7PD8bEEK0RUJiUSp1Zzn2nYyjmXGwHVD69DgkhXaFN7bkcz9_PoQcUTilQMuznxSaOi8p-30M7AQAGpGLPTKlgrOcVQI-pPNfZEIOQlhsIN6wfTKhrKyg4GxKzu-9GoNBP6g-GzB2dlB_XI9Z9KjigGPM7JhpFUP2ZGOXdesl-titvbPGhuET-diqPuDn3X5Ifn27vr_6kd_efb-5urzNtYAq5o1SBlDBjLfNrCxEpWtBW8ObWlGssWTC6BYrrhQUAIxREDXjRSGM0E1FZ_yQXGxzl6vZgEanXl71culTXb-WTln5_81oOzl3j5JCzdIqUsLXXYJ3DysMUQ42aOx7NaJbBVlxWrKKNQkUW1B7F4LH9vUVCnKjXr6olxuvEph8US9Fmvvyb8W3qZ3rBLAtENQc5cKt_JiUvZu6-zgmu48WvQza4qjRWI86SuPsOwnPyfakOw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73162729</pqid></control><display><type>article</type><title>Transdermal methimazole treatment in cats with hyperthyroidism</title><source>Sage Journals GOLD Open Access 2024</source><creator>Hoffmann, G ; Marks, S.L ; Taboada, J ; Hosgood, G.L ; Wolfsheimer, K.J</creator><creatorcontrib>Hoffmann, G ; Marks, S.L ; Taboada, J ; Hosgood, G.L ; Wolfsheimer, K.J</creatorcontrib><description>The objectives of this study were to assess serum thyroxine concentrations and clinical response in hyperthyroid cats to treatment with transdermal methimazole, and to determine if further investigation is indicated.
Clinical and laboratory data from 13 cats with hyperthyroidism were retrospectively evaluated. Methimazole (Tapazole, Eli Lilly) was formulated in a pleuronic lecithin organogel (PLO)-based vehicle and was applied to the inner pinna of the ear at a dosage ranging from 2.5
mg/cat q 24
h to 10.0
mg/cat q 12
h. During the treatment period, cats were re-evaluated at a mean of 4.3 weeks (recheck-1), and again at a mean of 5.4 months (recheck-2).
Clinical improvement was observed, and significant decreases in thyroxine concentrations were measured at recheck-1 (mean: 39.57
nmol/L, SEM: 14.4, SD: 41.2) and recheck-2 (mean: 36.71
nmol/L, SEM: 13.9, SD: 45.56) compared to pretreatment concentrations (mean: 97.5
nmol/L, SEM: 11.42, SD: 39.5). No adverse effects were reported.</description><identifier>ISSN: 1098-612X</identifier><identifier>EISSN: 1532-2750</identifier><identifier>DOI: 10.1016/S1098-612X(02)00095-5</identifier><identifier>PMID: 12670432</identifier><language>eng</language><publisher>London, England: Elsevier Ltd</publisher><subject>Administration, Cutaneous ; Animals ; Antithyroid Agents - administration & dosage ; Antithyroid Agents - therapeutic use ; Cat Diseases - drug therapy ; Cat Diseases - pathology ; Cats ; Ear, External ; Female ; Hyperthyroidism - drug therapy ; Hyperthyroidism - veterinary ; Male ; Methimazole - administration & dosage ; Methimazole - therapeutic use ; Records - veterinary ; Retrospective Studies ; Thyroxine - blood ; Treatment Outcome</subject><ispartof>Journal of feline medicine and surgery, 2003-04, Vol.5 (2), p.77-82</ispartof><rights>2003 ESFM and AAFP</rights><rights>2003 International Society of Feline Medicine and American Association of Feline Practitioners</rights><rights>2003 International Society of Feline Medicine and American Association of Feline Practitioners 2003 International Society of Feline Medicine and American Association of Feline Practitioners</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c507t-9aad0ea0b3f9b6457c851fd398a1e8e625dcfe73aa040022105823445d5c971b3</citedby><cites>FETCH-LOGICAL-c507t-9aad0ea0b3f9b6457c851fd398a1e8e625dcfe73aa040022105823445d5c971b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10822224/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10822224/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,21964,27851,27922,27923,44943,45331,53789,53791</link.rule.ids><linktorsrc>$$Uhttps://journals.sagepub.com/doi/full/10.1016/S1098-612X(02)00095-5?utm_source=summon&utm_medium=discovery-provider$$EView_record_in_SAGE_Publications$$FView_record_in_$$GSAGE_Publications</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12670432$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hoffmann, G</creatorcontrib><creatorcontrib>Marks, S.L</creatorcontrib><creatorcontrib>Taboada, J</creatorcontrib><creatorcontrib>Hosgood, G.L</creatorcontrib><creatorcontrib>Wolfsheimer, K.J</creatorcontrib><title>Transdermal methimazole treatment in cats with hyperthyroidism</title><title>Journal of feline medicine and surgery</title><addtitle>J Feline Med Surg</addtitle><description>The objectives of this study were to assess serum thyroxine concentrations and clinical response in hyperthyroid cats to treatment with transdermal methimazole, and to determine if further investigation is indicated.
Clinical and laboratory data from 13 cats with hyperthyroidism were retrospectively evaluated. Methimazole (Tapazole, Eli Lilly) was formulated in a pleuronic lecithin organogel (PLO)-based vehicle and was applied to the inner pinna of the ear at a dosage ranging from 2.5
mg/cat q 24
h to 10.0
mg/cat q 12
h. During the treatment period, cats were re-evaluated at a mean of 4.3 weeks (recheck-1), and again at a mean of 5.4 months (recheck-2).
Clinical improvement was observed, and significant decreases in thyroxine concentrations were measured at recheck-1 (mean: 39.57
nmol/L, SEM: 14.4, SD: 41.2) and recheck-2 (mean: 36.71
nmol/L, SEM: 13.9, SD: 45.56) compared to pretreatment concentrations (mean: 97.5
nmol/L, SEM: 11.42, SD: 39.5). No adverse effects were reported.</description><subject>Administration, Cutaneous</subject><subject>Animals</subject><subject>Antithyroid Agents - administration & dosage</subject><subject>Antithyroid Agents - therapeutic use</subject><subject>Cat Diseases - drug therapy</subject><subject>Cat Diseases - pathology</subject><subject>Cats</subject><subject>Ear, External</subject><subject>Female</subject><subject>Hyperthyroidism - drug therapy</subject><subject>Hyperthyroidism - veterinary</subject><subject>Male</subject><subject>Methimazole - administration & dosage</subject><subject>Methimazole - therapeutic use</subject><subject>Records - veterinary</subject><subject>Retrospective Studies</subject><subject>Thyroxine - blood</subject><subject>Treatment Outcome</subject><issn>1098-612X</issn><issn>1532-2750</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkM1OGzEURi3UigTaR6CaVQWLgWt7PD8bEEK0RUJiUSp1Zzn2nYyjmXGwHVD69DgkhXaFN7bkcz9_PoQcUTilQMuznxSaOi8p-30M7AQAGpGLPTKlgrOcVQI-pPNfZEIOQlhsIN6wfTKhrKyg4GxKzu-9GoNBP6g-GzB2dlB_XI9Z9KjigGPM7JhpFUP2ZGOXdesl-titvbPGhuET-diqPuDn3X5Ifn27vr_6kd_efb-5urzNtYAq5o1SBlDBjLfNrCxEpWtBW8ObWlGssWTC6BYrrhQUAIxREDXjRSGM0E1FZ_yQXGxzl6vZgEanXl71culTXb-WTln5_81oOzl3j5JCzdIqUsLXXYJ3DysMUQ42aOx7NaJbBVlxWrKKNQkUW1B7F4LH9vUVCnKjXr6olxuvEph8US9Fmvvyb8W3qZ3rBLAtENQc5cKt_JiUvZu6-zgmu48WvQza4qjRWI86SuPsOwnPyfakOw</recordid><startdate>20030401</startdate><enddate>20030401</enddate><creator>Hoffmann, G</creator><creator>Marks, S.L</creator><creator>Taboada, J</creator><creator>Hosgood, G.L</creator><creator>Wolfsheimer, K.J</creator><general>Elsevier Ltd</general><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20030401</creationdate><title>Transdermal methimazole treatment in cats with hyperthyroidism</title><author>Hoffmann, G ; Marks, S.L ; Taboada, J ; Hosgood, G.L ; Wolfsheimer, K.J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c507t-9aad0ea0b3f9b6457c851fd398a1e8e625dcfe73aa040022105823445d5c971b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Administration, Cutaneous</topic><topic>Animals</topic><topic>Antithyroid Agents - administration & dosage</topic><topic>Antithyroid Agents - therapeutic use</topic><topic>Cat Diseases - drug therapy</topic><topic>Cat Diseases - pathology</topic><topic>Cats</topic><topic>Ear, External</topic><topic>Female</topic><topic>Hyperthyroidism - drug therapy</topic><topic>Hyperthyroidism - veterinary</topic><topic>Male</topic><topic>Methimazole - administration & dosage</topic><topic>Methimazole - therapeutic use</topic><topic>Records - veterinary</topic><topic>Retrospective Studies</topic><topic>Thyroxine - blood</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hoffmann, G</creatorcontrib><creatorcontrib>Marks, S.L</creatorcontrib><creatorcontrib>Taboada, J</creatorcontrib><creatorcontrib>Hosgood, G.L</creatorcontrib><creatorcontrib>Wolfsheimer, K.J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of feline medicine and surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Hoffmann, G</au><au>Marks, S.L</au><au>Taboada, J</au><au>Hosgood, G.L</au><au>Wolfsheimer, K.J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Transdermal methimazole treatment in cats with hyperthyroidism</atitle><jtitle>Journal of feline medicine and surgery</jtitle><addtitle>J Feline Med Surg</addtitle><date>2003-04-01</date><risdate>2003</risdate><volume>5</volume><issue>2</issue><spage>77</spage><epage>82</epage><pages>77-82</pages><issn>1098-612X</issn><eissn>1532-2750</eissn><abstract>The objectives of this study were to assess serum thyroxine concentrations and clinical response in hyperthyroid cats to treatment with transdermal methimazole, and to determine if further investigation is indicated.
Clinical and laboratory data from 13 cats with hyperthyroidism were retrospectively evaluated. Methimazole (Tapazole, Eli Lilly) was formulated in a pleuronic lecithin organogel (PLO)-based vehicle and was applied to the inner pinna of the ear at a dosage ranging from 2.5
mg/cat q 24
h to 10.0
mg/cat q 12
h. During the treatment period, cats were re-evaluated at a mean of 4.3 weeks (recheck-1), and again at a mean of 5.4 months (recheck-2).
Clinical improvement was observed, and significant decreases in thyroxine concentrations were measured at recheck-1 (mean: 39.57
nmol/L, SEM: 14.4, SD: 41.2) and recheck-2 (mean: 36.71
nmol/L, SEM: 13.9, SD: 45.56) compared to pretreatment concentrations (mean: 97.5
nmol/L, SEM: 11.42, SD: 39.5). No adverse effects were reported.</abstract><cop>London, England</cop><pub>Elsevier Ltd</pub><pmid>12670432</pmid><doi>10.1016/S1098-612X(02)00095-5</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 1098-612X |
| ispartof | Journal of feline medicine and surgery, 2003-04, Vol.5 (2), p.77-82 |
| issn | 1098-612X 1532-2750 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10822224 |
| source | Sage Journals GOLD Open Access 2024 |
| subjects | Administration, Cutaneous Animals Antithyroid Agents - administration & dosage Antithyroid Agents - therapeutic use Cat Diseases - drug therapy Cat Diseases - pathology Cats Ear, External Female Hyperthyroidism - drug therapy Hyperthyroidism - veterinary Male Methimazole - administration & dosage Methimazole - therapeutic use Records - veterinary Retrospective Studies Thyroxine - blood Treatment Outcome |
| title | Transdermal methimazole treatment in cats with hyperthyroidism |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T04%3A52%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_AFRWT&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Transdermal%20methimazole%20treatment%20in%20cats%20with%20hyperthyroidism&rft.jtitle=Journal%20of%20feline%20medicine%20and%20surgery&rft.au=Hoffmann,%20G&rft.date=2003-04-01&rft.volume=5&rft.issue=2&rft.spage=77&rft.epage=82&rft.pages=77-82&rft.issn=1098-612X&rft.eissn=1532-2750&rft_id=info:doi/10.1016/S1098-612X(02)00095-5&rft_dat=%3Cproquest_AFRWT%3E73162729%3C/proquest_AFRWT%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73162729&rft_id=info:pmid/12670432&rft_sage_id=10.1016_S1098-612X(02)00095-5&rft_els_id=S1098612X02000955&rfr_iscdi=true |